| Chronic Obstructive Airway Disease
Anoro Ellipta vs Nucala
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Anoro Ellipta vs Nucala with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNucala has a higher rate of injection site reactions vs Anoro Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nucala but not Anoro Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Anoro Ellipta
Nucala
At A Glance
Oral inhalation
Once daily
LAMA/LABA
SC injection
Every 4 weeks
IL-5 antagonist
Indications
- Chronic Obstructive Airway Disease
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Chronic Obstructive Airway Disease
- Eosinophilic granulomatosis with polyangiitis
- Hypereosinophilic syndrome
Dosing
Chronic Obstructive Airway Disease 62.5 mcg umeclidinium and 25 mcg vilanterol (1 actuation of ANORO ELLIPTA 62.5/25 mcg) once daily by oral inhalation; do not use more than 1 time every 24 hours.
Asthma (>=12 years), Chronic rhinosinusitis with multiple nasal polyps, Chronic Obstructive Airway Disease 100 mg SC once every 4 weeks.
Asthma (6-11 years) 40 mg SC once every 4 weeks.
Eosinophilic granulomatosis with polyangiitis, Hypereosinophilic syndrome 300 mg SC once every 4 weeks, administered as 3 separate 100 mg injections at least 5 cm apart.
Contraindications
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to umeclidinium, vilanterol, or any excipient
- Use of a long-acting beta2-adrenergic agonist (LABA) without an inhaled corticosteroid (ICS) in patients with asthma
- History of hypersensitivity to mepolizumab or excipients in the formulation
Adverse Reactions
Most common (>=1%) Pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck pain, chest pain
Serious Serious asthma-related events (hospitalizations, intubations, death), paradoxical bronchospasm, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Palpitations, blurred vision, eye pain, glaucoma, increased intraocular pressure, anaphylaxis, angioedema, urticaria, dysgeusia, tremor, anxiety, dysuria, urinary retention, dysphonia
Most common (>=3%) headache, injection site reaction, back pain, fatigue, oropharyngeal pain, arthralgia, diarrhea, urinary tract infection, cough, pruritus, eczema
Serious herpes zoster
Postmarketing hypersensitivity reactions including anaphylaxis
Pharmacology
Umeclidinium is a long-acting muscarinic antagonist (LAMA) that inhibits M3 receptors in airway smooth muscle to produce bronchodilation; vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase to increase cyclic AMP, relaxing bronchial smooth muscle and inhibiting mediator release from mast cells.
Mepolizumab is an IL-5 antagonist (IgG1 kappa) that binds IL-5 with high affinity, blocking its binding to the alpha chain of the IL-5 receptor complex on eosinophils, thereby inhibiting IL-5 signaling and reducing eosinophil production and survival.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Anoro Ellipta
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (11/12)
Nucala
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
UnitedHealthcare
Anoro Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Nucala
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Anoro Ellipta
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Nucala
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Anoro Ellipta.
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Anoro ElliptaView full Anoro Ellipta profile
NucalaView full Nucala profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.